Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma

Table 1

Results of RTK inhibitors used in Pediatric Preclinical Testing Program.

Intended target	Inhibitor	Additional targets	In vivo response, RMS xenografts∗	Conclusions	Ref.
EGFR, ErbB2	Lapatinib	Erk1/2, Akt	1/5	Limited effectiveness in all xenografts tested	[30]
IGF-1R	IMC-A12	N/A	6/6	Tumor growth inhibition in most solid tumor xenografts, most effective in RMS xenografts	[25]
IGF-1R	SCH 717454	N/A	2/4	Tumor growth inhibition in many solid tumor xenografts	[31]
PDGFR	Sunitinib	c-KIT, VEGFR2, FLT3	5/6	Tumor growth delay, inhibition in most solid tumor xenografts	[32]
Raf1	Sorafenib	VEGFR, PDGFR, RET, FLT3, c-KIT	2/6	Tumor growth inhibition in various tumor xenografts	[33]
SRC	Dasatinib	ABL, c-KIT, EPHA2, PDGFR	1/6	Limited effectiveness in solid tumor xenografts	[34]
VEGFR1-3	AZD2171	PDGFR, c-KIT	5/5	Tumor growth inhibition in most solid tumor xenografts	[35]

∗Xenografts with “intermediate” or “high” response activity as defined by Maris et al. [50].